Incidence of and Mortality Due to Human Prion Diseases in Taiwan: A Prospective 20-Year Nationwide Surveillance Study from 1998 to 2017

Figures & data

Figure 1 Annual Incidence Rate of all CJD Patients by Gender and Age. The incidences increased with increasing age, reaching a peak at the age of 70–79 years in both men and women; the incidence among patients aged 80 and above was still high; low incidence rate observed below 50 years.

Table 1 Biennial Incidence (A) and Mortality Rate (B) per 1,000,000 Persons of CJD in Taiwan from 1998 to 2017

(A) Incidence
	Crude Annual Incidence in 2-Year Period										Total (1998–2017)
	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017	No. of Cases	Crude incidence (95% CI)	Age-adjusted incidence^a (95% CI)
Men	0.35	0.44	0.65	0.61	0.34	0.95	0.99	1.41	0.73	1.19	178	0.77(0.66-0.88)	0.77(0.61-0.93)
Women	0.65	0.55	0.41	0.40	0.75	0.92	0.78	1.07	1.15	1.10	178	0.78(0.67-0.90)	0.82(0.65-0.98)
Total	0.50	0.49	0.53	0.51	0.55	0.93	0.88	1.24	0.94	1.15	356	0.78(0.70-0.86)	0.79(0.68-0.91)
(B) Mortality
	Crude Annual Mortality in 2-Year Period										Total (1998–2017)
	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017	No. of Deaths	Crude mortality (95% CI)	Age-adjusted mortality^a (95% CI)
Men	0.49	0.44	0.35	0.56	0.52	0.69	0.82	1.24	0.85	1.15	165	0.71(0.60-0.82)	0.71(0.56-0.87)
Women	0.61	0.46	0.45	0.40	0.44	0.52	0.65	1.29	1.11	1.06	160	0.71(0.60-0.81)	0.74(0.58-0.89)
Total	0.55	0.45	0.40	0.48	0.48	0.61	0.73	1.26	0.98	1.10	325	0.71(0.63-0.79)	0.72(0.61-0.83)

Note: ^aAge-adjusted incidence and mortality were calculated with the use of Taiwan census data in 2010.

Figure 2 Kaplan-Meier Survival Curves for Patients with Sporadic CJD by Age (A) and Gender (B). Kaplan-Meier curves display time from disease onset to death or to the end of 120 months. The 10-year cumulative survival rates for men and women were 0% and 2%, respectively. Longer survival time was noted in patients with younger age at onset (A), and in women than men (B).

Availability of data and material

The data and raw material could be available after an application to and approval from the Taiwan CDC.